Stage 2

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024
Vaccination, Public, Advisory Committee, Net, Ageing, Tolerability, Investment, PCV15, PCV, Safety, Phase 10, Infant, Infection, Trial of the century, Conference, Growth, Administration, Lonza, Immunization, Exercise, Research and development, Bank, ACIP, Stage 2, Initiate, PCV20, G&A, SAN, End, Genetically modified bacteria, IPD, Vaccine

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) --  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
  • The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
  • As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.

Bomboré Hard Rock Expansion Update and Three-Year Production Forecast

Retrieved on: 
Monday, May 6, 2024
Cell, OTCQX, Metallurgy, TSX, Carbon, Gold, Classification, CIL, Stage 2, Growth, Mining

VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide an update on its Phase II hard rock expansion and a three-year production forecast for its Bomboré Gold Mine located in central Burkina Faso.

Key Points: 
  • VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to provide an update on its Phase II hard rock expansion and a three-year production forecast for its Bomboré Gold Mine located in central Burkina Faso.
  • Stage 1 will consist of an initial 2.5Mtpa hard rock plant, with a subsequent Stage 2 expansion increasing the hard rock throughput to 5.0-7.0Mtpa.
  • The capital cost for the initial 2.5Mtpa hard rock plant is estimated at US$80 million, significantly less than the US$168 million estimated for the 4.4Mtpa hard rock plant, along with the benefit of a shorter overall construction timeline.
  • The Company expects to finance the costs of construction for this Stage 1 hard rock plant primarily through senior debt, with the balance from future operating cash flow.

Canada’s biomanufacturing ecosystem gets major boost with new funding

Retrieved on: 
Monday, May 6, 2024
SSHRC, University, Economy, Pandemic, Safety, Policy, CFI, École polytechnique, McMaster University, Partnership, Research, Vaccine, The Honourable, Social science, Public, Stage 2, Natural science, Pharmaceutical industry

“The projects funded through the Biosciences Research Infrastructure Fund will play a critical role in our country’s rapid response to future pandemics.

Key Points: 
  • “The projects funded through the Biosciences Research Infrastructure Fund will play a critical role in our country’s rapid response to future pandemics.
  • The integrated CBRF–BRIF Stage 2 competitions are advancing the goals of Canada's Biomanufacturing and Life Sciences Strategy .
  • The BRIF is partnered with the CBRF, which is funding research and talent development projects as part of today’s announcement.
  • A total of 19 projects at 14 institutions were awarded funding to support research, talent development or research infrastructure.

Energy Vault, ACEN Australia Announce Agreement for 400 MWh of Battery Energy Storage Deployments

Retrieved on: 
Thursday, May 9, 2024
Technology, Construction & Property, Batteries, Other Energy, Utilities, Other Technology, Green Technology, Alternative Energy, Environment, Energy, Other Construction & Property, NSW, NEM, S120, Electricity, BESS, Risk management, Engineering, Stage 2, National Electricity Market, ACEN, Energy Vault, Renewable energy

Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, and ACEN Australia, today announced the main contractual agreements for two battery energy storage system (BESS) deployments totaling 400 MWh in Australia.

Key Points: 
  • Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), a leader in sustainable, grid-scale energy storage solutions, and ACEN Australia, today announced the main contractual agreements for two battery energy storage system (BESS) deployments totaling 400 MWh in Australia.
  • Construction on both deployments is expected to begin in the second half of 2024, with commercial operations expected in 2025 and 2026.
  • Under the agreement, Energy Vault will deploy both a 50 MW/100 MWh BESS and a 150 MW/300 MWh BESS at ACEN Australia’s 720 MW New England Solar, one of the largest solar projects to participate in Australia’s National Electricity Market (NEM).
  • In 2023, ACEN Australia secured a 20 year Long Term Energy Service Agreement (LTESA) for New England Solar in the NSW Government’s first renewable energy and storage auction.

Government of Canada funds new projects to further grow the domestic biomanufacturing and life sciences sector

Retrieved on: 
Monday, May 6, 2024
SSHRC, Public, Economy, Ecosystem, Pandemic, Investment, Strategic Innovation Fund, Hospital, Bacteria, Research, RNA, Partnership, CIHR, Artificial intelligence, Vaccine, Humanities, The Honourable, Therapy, Social science, Stage 2, Clinical trial, Government, Natural science, Engineering, Pharmaceutical industry

MONTRÉAL, May 6, 2024 /CNW/ - Growing a robust, competitive, domestic biomanufacturing and life sciences sector ensures that Canada has access to critical vaccines, therapeutics and other life-saving medicines.

Key Points: 
  • MONTRÉAL, May 6, 2024 /CNW/ - Growing a robust, competitive, domestic biomanufacturing and life sciences sector ensures that Canada has access to critical vaccines, therapeutics and other life-saving medicines.
  • The Government of Canada has been doing just that since the launch of Canada's Biomanufacturing and Life Sciences Strategy in 2021 with a $2.2 billion commitment to develop cutting-edge biomanufacturing capabilities.
  • "With world-leading scientists and researchers established across Canadian leading research institutions, Canada is home to a competitive and robust biomanufacturing and life sciences sector.
  • Since the onset of the pandemic, the Government has invested more than $2.2 billion in 38 different projects in the biomanufacturing ecosystem .

International open competition launched to find a design team for the new museum of architecture and design in Helsinki, Finland

Retrieved on: 
Monday, April 15, 2024
GFA, Real estate, City, Esplanade Park, Jane, Estate (law), Heart, Urban renewal, Marimekko, Aino, Employment, History, A3, Public policy, Culture, Museum, Society, Jury, World Design Capital, ADM, Fiskars, UNESCO, SAFA, Nokia, Stage 2, Name, Running

An international open design competition is launched to find a design team for a new museum building on a site in Helsinki's South Harbour.

Key Points: 
  • An international open design competition is launched to find a design team for a new museum building on a site in Helsinki's South Harbour.
  • The building will provide a home for the new museum of architecture and design formed through the merger of the Design Museum Helsinki and the Museum of Finnish Architecture.
  • The new museum of architecture and design in Helsinki, Finland, is planned to open in 2030 and will combine the Museum of Finnish Architecture and Design Museum Helsinki.
  • We're delighted to launch this international open competition to find an architect for the new museum of architecture and design.

ProvisionAi Hosts Theatre Session on Supply Chain Challenges at the Gartner Supply Chain Symposium/Xpo™

Retrieved on: 
Thursday, April 4, 2024
Kimberly-Clark, Intelligence, APO, SAP, Transport, Carbon, Consultant, Supply, Supply chain, Stage 2, Walt Disney, Procter & Gamble, Gartner, Renewable energy

Put more formally, ProvisionAi closes the gap between transportation planning and execution to smooth deployment, match loads to demand, and respect complex supply chain constraints," says Tom Moore, CEO and Founder of ProvisionAi.

Key Points: 
  • Put more formally, ProvisionAi closes the gap between transportation planning and execution to smooth deployment, match loads to demand, and respect complex supply chain constraints," says Tom Moore, CEO and Founder of ProvisionAi.
  • The Gartner Supply Chain Symposium/Xpo happens May 6 – 8, 2024, at the Walt Disney World Swan and Dolphin Resort in Orlando, FL.
  • His expertise facilitated pivotal Supply Chain system implementations across NA and Europe notably in SAP OTC, APO, and Kinaxis Rapid Response.
  • His multifaceted background uniquely positions him as a leader who understands the challenges and opportunities within the supply chain ecosystem.

Kharmagtai Water Supply Drilling Program Recommences

Retrieved on: 
Wednesday, March 27, 2024
Water supply, SRK, Growth, Hydrology, Mineral Resources Limited, ZUK, Disclosure, XAM, Data, ASX, Groundwater, Permeability, TSX, SABC, Rio Tinto, Water, PFS, Stage 2, Mining, Tunnel

Water supply is a core input to the study; a key driver to maximise processing throughput for the project.

Key Points: 
  • Water supply is a core input to the study; a key driver to maximise processing throughput for the project.
  • We are confident in this field program and aim to demonstrate that, to a PFS standard, there is an adequate supply of water for Kharmagtai, to ensure its successful delivery as Mongolia’s next major copper-gold mine in the south Gobi region of Mongolia.”
    The hydrological program has six key objectives to provide water supply for Kharmagtai operations.
  • The Kharmagtai PFS seeks to maximise water recycling through the use of industry best practices including efficient process design, modern tailings dam design and thickened tailings to reduce water loss.
  • The order of monitoring bore drilling will change as the field program progresses, including progress of production bore drilling.

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Biopsy, NSCLC, Entrepreneurship, Carcinoma, DLL4, Patient, Neoplasm, PET, Merck, G&A, Doctor of Philosophy, MD, Insurance, IND, Mesothelioma, Research and development, CD137, Therapy, Paclitaxel, BTC, CRC, Melanoma, Stage 2, PD-L1, FDA, SCLC, PD-1, Pharmaceutical industry

Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.

Key Points: 
  • Ended 2023 with $152 million in cash and marketable securities, which is expected to provide cash runway into mid-year 2026.
  • BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update.
  • The increase was primarily attributable to higher stock compensation expense of $1.0 million offset by lower insurance costs of $0.3 million.
  • During 2023, the Company decreased its cash position by $34.1 million, primarily from $40.6 million of net cash used in operating activities.

Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress

Retrieved on: 
Monday, March 18, 2024
Research, TNF, AON, Dexamethasone, Congress, International, International Financial Reporting Standards, Telecanthus, Inflammation, DME, Patient, SNP, NDA, American Academy, G&A, POC, Business analyst, IND, Abstract, DED, Bank statement, Genotype, Investment, Retina, Diabetic retinopathy, OCS, Safety, CHF, Pain, Stage 2, Pharmaceutical industry

Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.

Key Points: 
  • Riad Sherif M.D., Chief Executive Officer of Oculis: “2023 was a remarkable milestone-rich year for Oculis.
  • These non-IFRS financial measures exclude the impact of items that the Company’s management believes affect comparability or underlying business trends.
  • The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.
  • The resulting non-cash foreign exchange impact of such reclassification amounted to CHF 5.0 million or $5.7 million for the year ended December 31, 2023.